Skip to main content
All lobbying filings

PFIZER INC.

Lobbying for PFIZER INC.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $1,880,000.00 expenses · posted Jul 20, 2026

Official filing document

 Bills named in this filing 12
  • S 2658
    Medication Affordability and Patent Integrity Act
  • HR 7837
    Most Favored Patient Act of 2026
  • HR 7391
    Community Health Center Drug Pricing Protection Act
  • HR 8646
    Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
  • HR 9260
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
  • HR 5178
    Sickle Cell Disease Comprehensive Care Act
  • HR 5526
    Biosimilar Red Tape Elimination Act
  • HR 4930
    To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • HR 9102
    BINSA Act
 Lobbying activity 5
Copyright/Patent/Trademark

Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act

Health Issues

Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage

Medicare/Medicaid

H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues

Taxation/Internal Revenue Code

H.R. 1 - An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14

Trade (domestic/foreign)

H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem